Summary:
The primary objective of this study is to demonstrate the superiority of sotagliflozin 400mg versus placebo on hemaglobin A1C (HbA1c) reduction at Week 26 in patients with type 2 diabetes mellitus (T2D) who have inadequate glycemic control with metformin.
Qualified Participants Must:
• Currently be taking Metfomin for control of Diabetes
•
Not be taking any medications intended to promote weight loss
•
Have no prior history of insulin use exceeding 1 month
Qualified Participants May Receive:
- Compensation for time and travel expenses
- Study medication
- Physicals performed by a board certified physician
- Lab work